Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide.

A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are ...

An Eli Lilly exec said the company’s experimental weight-loss pill could make GLP-1 treatments more accessible worldwide, as ...

After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they ...

Mehmet Oz will likely face questions during his confirmation hearing about his past support of expanding the Medicare ...

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

Kennedy Jr., who was tapped to lead the Department of Health and Human Services for the Trump administration, recently ...

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...

Roche (RHHBY) is increasing its investment into the obesity space with an up to $5.3 billion deal with Danish drugmaker ...

Analysts acknowledged the long-term manufacturing deal could dull Viking’s takeout prospects but hailed it as a smart move to ensure supply.

Like many pharma stocks, Eli Lilly (NYSE: LLY) offers investors a bit of safety -- and it's an element you can count on ...

The diabetes and weight loss drug market is heating up in 2025, with significant growth signs everywhere. According to a recent study from Research and Markets, industry growth is running at an ...